Pharmaceutical and Healthcare latest pipeline guide Onychomycosis (Tinea Unguium) – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Onychomycosis (Tinea Unguium) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Onychomycosis Pipeline (Tinea Unguium )Review, H2 2017, provides an overview of the Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline landscape.
Onychomycosis is a chronic fungal infection of the nails caused by dermatophytes. Symptoms include thickened nail that is difficult to cut, brittle or ragged nail, discolored or unsightly nail and pain of the finger or toe with ordinary activities. Treatment includes antifungal medications and surgery.
Purchase This Single User License PDF Report of 67 pages at: http://www.reportsnreports.com/purchase.aspx?name=1132634 .
The Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Onychomycosis (Tinea Unguium) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical, Discovery and Unknown stages are 1, 2, 6, 3, 3 and 1 respectively.
Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Discount is available on Onychomycosis report at http://www.reportsnreports.com/contacts/discount.aspx?name=1132634 .
Onychomycosis (Tinea Unguium) – Companies Involved in Therapeutics Development
Almirall SA, Arno Therapeutics Inc, Blueberry Therapeutics Ltd, Dermala Inc, Eisai Co Ltd, Helix BioMedix Inc, Hexima Ltd, Meiji Seika Pharma Co Ltd, Moberg Pharma AB, NAL Pharmaceuticals Ltd, Novabiotics Ltd, Novan Inc, Viamet Pharmaceuticals Inc
List of Figures
Number of Products under Development for Onychomycosis (Tinea Unguium), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
ReportsandReports.com is your single source for all market research needs. Our database includes 100,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
2nd Floor, Metropole,
Bund Garden Road,
Pune – 411001,
Tel: + 1 888 391 5441